Clinical Application of Circulating Tumor Cells

Overview

Journal Med Genet

Publisher De Gruyter

Specialties Genetics
Medical Ethics

Date 2024 Jun 5

PMID 38835741

Authors

Nikolas H Stoecklein

Julia Oles

Andre Franken

Hans Neubauer

Leon W M M Terstappen

Rui P L Neves

Affiliations

Soon will be listed here.

Abstract

This narrative review aims to provide a comprehensive overview of the current state of circulating tumor cell (CTC) analysis and its clinical significance in patients with epithelial cancers. The review explores the advancements in CTC detection methods, their clinical applications, and the challenges that lie ahead. By examining the important research findings in this field, this review offers the reader a solid foundation to understand the evolving landscape of CTC analysis and its potential implications for clinical practice. The comprehensive analysis of CTCs provides valuable insights into tumor biology, treatment response, minimal residual disease detection, and prognostic evaluation. Furthermore, the review highlights the potential of CTCs as a non-invasive biomarker for personalized medicine and the monitoring of treatment efficacy. Despite the progress made in CTC research, several challenges such as standardization, validation, and integration into routine clinical practice remain. The review concludes by discussing future directions and the potential impact of CTC analysis on improving patient outcomes and guiding therapeutic decision-making in epithelial cancers.

Citing Articles

Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?.

Fabisiewicz A, Szostakowska-Rodzos M, Grzybowska E Int J Mol Sci. 2024; 25(19).

PMID: 39408942 PMC: 11476589. DOI: 10.3390/ijms251910612.

Liquid Biopsy: minimal-invasive analysis of somatic alterations.

Hallermayr A Med Genet. 2024; 35(4):199-200.

PMID: 38835738 PMC: 11006306. DOI: 10.1515/medgen-2023-2061.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

References

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A . Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. Clin Chem. 2019; 65(4):549-558. DOI: 10.1373/clinchem.2018.296814. View

Pantel K . Blood tests for early detection of lung cancer: challenges and promises. Lancet Respir Med. 2020; 8(7):654-656. DOI: 10.1016/S2213-2600(20)30115-6. View

Neves R, Ammerlaan W, Andree K, Bender S, Cayrefourcq L, Driemel C . Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. Clin Chem. 2021; 67(4):631-641. DOI: 10.1093/clinchem/hvaa322. View

Hugenschmidt H, Labori K, Brunborg C, Verbeke C, Thomas Seeberg L, Schirmer C . Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. Ann Surg. 2018; 271(3):549-558. DOI: 10.1097/SLA.0000000000003035. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A . Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer. 1999; 81(5):870-3. PMC: 2374287. DOI: 10.1038/sj.bjc.6690778. View

Kolinsky M, Stoecklein N, Lambros M, Gil V, Nava Rodrigues D, Carreira S . Genetic Analysis of Circulating Tumour Cells. Recent Results Cancer Res. 2019; 215:57-76. DOI: 10.1007/978-3-030-26439-0_3. View

Visal T, den Hollander P, Cristofanilli M, Mani S . Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. Br J Cancer. 2022; 127(2):173-184. PMC: 9296521. DOI: 10.1038/s41416-022-01768-9. View

Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A . Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014; 6(11):1371-86. PMC: 4237466. DOI: 10.15252/emmm.201404033. View

10.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

11.

Campton D, Ramirez A, Nordberg J, Drovetto N, Clein A, Varshavskaya P . High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015; 15:360. PMC: 4430903. DOI: 10.1186/s12885-015-1383-x. View

12.

Dong L, Du X, Lu C, Zhang Z, Huang C, Yang L . RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients. Mater Today Bio. 2022; 17:100474. PMC: 9679687. DOI: 10.1016/j.mtbio.2022.100474. View

13.

Gires O, Stoecklein N . Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci. 2014; 71(22):4393-402. PMC: 11113679. DOI: 10.1007/s00018-014-1693-1. View

14.

Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A . Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013; 80(17):1598-605. PMC: 3662321. DOI: 10.1212/WNL.0b013e31828f183f. View

15.

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E . In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and Point Mutations in Circulating Tumor Cells. Clin Chem. 2018; 64(3):536-546. DOI: 10.1373/clinchem.2017.281295. View

16.

Muller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E . Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14(4):R118. PMC: 3680931. DOI: 10.1186/bcr3243. View

17.

Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y . PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Cancer Res. 2023; 29(10):1929-1937. PMC: 10192124. DOI: 10.1158/1078-0432.CCR-22-3233. View

18.

Nakasu Y, Deguchi S, Nakasu S, Yamazaki M, Notsu A, Mitsuya K . Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis. Neurooncol Adv. 2023; 5(1):vdad002. PMC: 10034915. DOI: 10.1093/noajnl/vdad002. View

19.

Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T . Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018; 29(8):1777-1783. DOI: 10.1093/annonc/mdy211. View

20.

Thege F, Gruber C, Cardle I, Cong S, Lannin T, Kirby B . anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform. Anal Biochem. 2019; 577:26-33. DOI: 10.1016/j.ab.2019.02.003. View